# MAXVAX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/maxvax

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.maxvax.cn
- Total disclosed funding: $159M
- Latest round: Series D (Dec 25, 2025)
- Investors on record: 19

## About

Established in 2016 and based in Chengdu, China, Chengdu Maikekang BioTechnology Co., Ltd., dba Maxhealth or MAXVAX, is a biotechnology company that focuses on the development of vaccines, and adjuvants. Dr. Dexiang Chen, the company's founder, has worked in Wyeth, Novartis, and PATH international public health agencies, and has 30 years of vaccine development experience. The R&D centers have been set up in Shanghai, Chengdu, and Hangzhou, and it has a production base in Shanghai Lingang New Area. The company has acquired certifications such as Specialized, Refined, Featured, and Original SMEs and the national high-tech enterprise. In December 2025, MAXVAX closed Series D+ funding from new investors Chengdu Science and Technology Venture Capital Group, BIO-TOWN Capital, returning investor Shenzhen Capital Real Estate Fund and other investor.

The company is engaged in the research, development, production, marketing, and sale of a new influenza vaccine, a new rabies vaccine, a new rotavirus vaccine, and a new shingles vaccine for the elderly. Its self-developed biotechnology platforms include an adjuvant technology platform, a recombinant protein platform, and an mRNA technology platform.

The company generates revenue by providing vaccines and immunotherapies.

The company will use the venture debt for the research and development of adjuvant platforms, construction of adjuvant workshops, vaccine clinical trials, preclinical research and development of vaccine pipelines, and international cooperation.

## Funding rounds

- Series D, Dec 25, 2025 — Chengdu Science and Technology Venture Capital Group, Shenzhen Capital Real Estate Fund, BIO-TOWN Capital
- Series D, Oct 31, 2025 — IDG Capital, Tianjin Ringpu Bio-technology, Shenzhen Capital Real Estate Fund
- Series C, Jun 10, 2024 — IDG Capital, Qianhai Ark Capital, Hankang Capital
- Series C, Feb 6, 2024, $42M — Shenzhen Capital Real Estate Fund
- Series B, Dec 7, 2022, $43M — Sealand Innovation, Gortune Investment, China Life Capital, GF Qianhe, Xinshang Investment, LongRiver Investments
- Series B, Jul 20, 2022, $74M — China Life Capital, Sherpa Healthcare Partners, GL Ventures, Xinshang Investment
- Series A, Jul 21, 2021 — Sherpa Healthcare Partners, Korea Investment Partners (China), Zhiyang Capital
- Angel, Dec 19, 2017 — Sichuan Venture Capital, Chengdu Bonuo Biotechnology

## Investors

- Sichuan Venture Capital (https://capitalatlas.ai/funds/sichuan-venture-capital) — Angel
- Chengdu Bonuo Biotechnology — Angel
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series A, Series B
- Korea Investment Partners (China) (https://capitalatlas.ai/funds/korea-investment-partners-china) — Series A
- Zhiyang Capital — Series A
- China Life Capital — Series B
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series B
- Xinshang Investment (https://capitalatlas.ai/funds/xinshang-investment) — Series B
- Sealand Innovation (https://capitalatlas.ai/funds/sealand-innovation) — Series B
- Gortune Investment (https://capitalatlas.ai/funds/gortune-investment) — Series B
- GF Qianhe — Series B
- LongRiver Investments (https://capitalatlas.ai/funds/longriver-investments) — Series B
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series C, Series D
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series C, Series D
- Qianhai Ark Capital (https://capitalatlas.ai/funds/qianhai-ark-capital) — Series C
- Hankang Capital (https://capitalatlas.ai/funds/hankang-capital) — Series C
- Tianjin Ringpu Bio-technology — Series D
- Chengdu Science and Technology Venture Capital Group (https://capitalatlas.ai/funds/chengdu-science-and-technology-venture-capital-group) — Series D
- BIO-TOWN Capital (https://capitalatlas.ai/funds/bio-town-capital) — Series D